



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARGS

Last Trade: 0.29

Trade Time: 3:59 PM ET
Apr 20, 2018

Change: -0.05  (-13.824%)

Day Range 0.27 - 0.36

52-Week Range 0.32 - 11.60

Volume 3,023,989

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 19, 2018

[Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives](#)

Apr 2, 2018

[Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights](#)

Mar 28, 2018

[Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018](#)

Feb 15, 2018

[Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy](#)

Feb 5, 2018

[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)

Financials [\[View all \]](#)

Apr 2, 2018

[Annual Report \(10-K\)](#)

Jul 6, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)